VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2021 | BrainStorm: improving prediction, diagnosis and management of brain metastases

Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, shares an update on the BrainStorm Program (NCT04109131), a clinical research platform which aims to optimize the treatment and management of patients with brain metastases. The study, which is performing MRIs and liquid biopsies and using cerebrospinal fluid (CSF) and circulating tumor DNA, aims to improve our understanding and prediction of the development of brain metastases, as well as enabling earlier diagnosis. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.


Ahmad Awada, MD, PhD, has participated in an advisory role, has received institutional research grants, or has received speakers fees from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck and Daiichi.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter